HTB

COVID-19: investigational drugs

No benefit from TDF/FTC against COVID-19

Major review finds little benefit of remdesivir in people hospitalised with COVID-19

UK RECOVERY study shows no benefit from aspirin in people hospitalised with COVID-19

WHO advises against use of convalescent plasma for COVID-19

Colchicine: no clinical benefits against COVID-19 in pooled analysis of RCTs

Eli Lilly withdraw EU application for bNAbs etesevimab and bamlanivimab

Early efficacy results with oral molnupiravir focuses attention on price and access

NHS supports selected use of inhaled budesonide for COVID-19 in people at risk of severe events

Reviews of ivermectin for COVID-19: no evidence of benefit from RCTs

RCT shows no impact of azithromycin in reducing symptoms of mild COVID-19

Research approach to rapidly review candidate treatments for COVID-19: nine studies using ACTIV protocol

COVID-19 treatment: tofacitinib, REGN bNAbs, convalescent plasma

Dexamethasone: final results from RECOVERY study

No impact from anakinra in mild/moderate COVID-19 pneumonia

CROI 2021: New compounds for prevention and treatment of COVID-19

Oral molnupiravir at higher dose reduces SARS-CoV-2 viral load at day five in small phase 2 study

Bamlanivimab prophylaxis reduces hospitalisation and mortality: results from phase 3 BLAZE-2 study

Dual Eli-Lilly mAb bamlanivimab and etesevimab reduces hospitalisation after single infusion: results from BLAZE-1 study

Dual Regeneron mAbs casirivimab with imdevimab reduce transmission: interim results from phase 3 study

CROI 2021: Urgency of global access to vaccines, the potential of mAbs and the lessons learned from HIV

Baricitinib improves recovery in sub-group of adults hospitalised COVID-19: results from ACTT-2 study

Ivermectin has no impact in treating mild COVID-19 in 400 adults in Columbia

No benefit from BRII and GSK monoclonal antibodies against COVID-19 in ACTIV-3 study

Tocilizimab effectively reduces COVID-19 related deaths and hospitalisation time: additive benefit with dexamethasone

Bamlanivimab (LY-CoV555) prophylaxis prevents COVID-19 in care homes: results of BLAZE-2 study

US FDA specifies high antibody titre for convalescent plasma and to only use in early COVID-19

No benefit from convalescent plasma in UK RECOVERY study: limited results restrict implications for COVID-19

Merck/MSD withdraws two vaccine candidates from further research but continues focus on treatment

Oral colchicine reduces hospitalisation in international randomised phase 3 outpatient study

IL-6 agonists tocilizumab and sarilumab reduces mortality in severe COVID-19: interim results from REMAP-CAP study

Two different dual antibody treatments each reduce SARS-CoV-2 viral load by >0.5 log

IV methylprednisolone pulse treatment for hospitalised severe COVID-19

Monoclonal antibody bamlanivimab is not effective in advanced COVID-19: lack of early signal stops study early

Azithromycin monotherapy shows no benefit for COVID-19: RECOVERY study reports 1493 further deaths

JAK inhibitor baricitinib in moderate/severe COVID-19 

Hydroxychloroquine fails to prevent COVID-19 or SARS-CoV-2 transmission when used as PEP

Hydroxychloroquine has no benefit on symptoms at 14 days

WHO SOLIDARITY study published in NEJM

International COVID-19 study launches in Africa but with drugs that have little chance of working (ANTICOV)

Remdesivir given full approval by the US FDA, but on limited data

DSMB stops REGN-COV2 (casirivimab/imdevimab) monoclonal antibody study in people with high-flow oxygen or ventilation: implications for UK RECOVERY study

Monoclonal antibody stopped in ACTIV-3 study: bamlanivimab shows lack of benefit in people hospitalised with COVID-19

Convalescent plasma: randomised controlled study finds no benefit in moderate stage COVID-19

No survival benefit from remdesivir, hydroxychloroquine, lopinavir/r or interferon-β1a in moderate and severe COVID-19: interim results from the WHO SOLIDARITY study

COVID-19: pathogenesis and treatment 

Tocilizumab fails to meet clinical endpoints in randomised COVACTA study: other studies continue

Tocilizumab associated with better outcomes from COVID-19 in US study

Famotidine associated with better outcomes from COVID-19

INSIGHT network to study monoclonal antibodies for COVID-19 including LY-CoV555

HepC drugs for COVID-19: sofosbuvir/daclatasvir show faster recovery and reduced mortality

Predictors of response to remdesivir in GS-5773 COVID-19 study

UK study reports inhaled interferon-Beta reduces time to recovery from COVID-19

EMA grants conditional approval for remdesivir in the EU to treat COVID-19

RECOVERY study reports that lopinavir/r fails to show benefit against COVID-19

Hydroxychloroquine and lopinavir/r arms stopped in the WHO SOLIDARITY study

Individualising management of COVID-19 based on real-time inflammatory responses

Further positive reports from tocilizumab to treat COVID-19

Dexamethasone significantly reduces mortality in subset of patients hospitalised with advanced COVID-19: UK RECOVERY study

Modelling paper suggests hydroxychloroquine dosing was too low to be active against COVID-19 and that higher doses would risk toxicity

FDA contraindication for remdesivir and hydroxychloroquine (HCQ): immediate impact on current HCQ research

UK RECOVERY study stops hydroxychloroquine (HCQ) for COVID-19: more than 1100 deaths question ethics and safety overall

SIMPLE study reports benefit from 5-day but not 10-day remdesivir on moderate COVID-19

Recent papers on convalescent plasma and on ACE inhibitors and angiotensin receptor blockers

Remdesivir improves recovery time in early COVID-19 infection: first definitive results of benefit

Convalescent plasma therapy for COVID-19

Post navigation